CYP.AX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 apr 2024 @ 05:14):

Stats
Dagens volum	84 453.00
Gjennomsnittsvolum	173 845
Markedsverdi	37.72M
EPS	$0 ( 2024-02-26 )
Neste inntjeningsdato	( $0 ) 2024-07-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.33
ATR14	$0.00200 (0.95%)

Cynata Therapeutics Ltd Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Cynata Therapeutics Ltd Økonomi

Annual	2023
Omsetning:	$1.65M
Bruttogevinst:	$1.37M (83.08 %)
EPS:	$-0.0984

FY	2023
Omsetning:	$1.65M
Bruttogevinst:	$1.37M (83.08 %)
EPS:	$-0.0984

FY	2022
Omsetning:	$7.77M
Bruttogevinst:	$7.49M (96.40 %)
EPS:	$-0.0380

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.0590

Financial Reports:

No articles found.

Cynata Therapeutics Ltd

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.